Libtayo

Regeneron's Libtayo posts lung cancer win with Bristol's Yervoy. But company won't seek approval
Regeneron's Libtayo posts lung cancer win with Bristol's Yervoy. But company won't seek approval
Fierce Pharma
Regeneron
Libtayo
non-small cell lung cancer
Bristol Myers Squibb
Yervoy
Flag link:
Catching up with Keytruda, Regeneron scores frontline NSCLC approval for Libtayo/chemo combo
Catching up with Keytruda, Regeneron scores frontline NSCLC approval for Libtayo/chemo combo
Endpoints
Regeneron
Libtayo
non-small cell lung cancer
Keytruda
Merck
Flag link:
Regeneron Highlights Plug-and-Play Oncology Strategy at ESMO
Regeneron Highlights Plug-and-Play Oncology Strategy at ESMO
BioSpace
ESMO
Regeneron
Libtayo
Flag link:
Regeneron completes acquisition of Sanofi’s stake in Libtayo
Regeneron completes acquisition of Sanofi’s stake in Libtayo
Pharmaceutical Business Review
Regeneron
Sanofi
Libtayo
cancer
Flag link:
Regeneron purchases Sanofi’s stake in Libtayo collaboration
Regeneron purchases Sanofi’s stake in Libtayo collaboration
Biopharma Reporter
Regeneron
Sanofi
Libtayo
Flag link:
BioNTech and Regeneron expand their cancer partnership, pushing new Libtayo combo into NSCLC
BioNTech and Regeneron expand their cancer partnership, pushing new Libtayo combo into NSCLC
Endpoints
BioNTech
Regeneron
lung cancer
vaccines
MRNA
Libtayo
Flag link:
Regeneron and Sanofi pull Libtayo app in cervical cancer, citing post-market study disagreement with FDA
Regeneron and Sanofi pull Libtayo app in cervical cancer, citing post-market study disagreement with FDA
Endpoints
Sanofi
Regeneron
Libtayo
cervical cancer
post-marketing studies
Flag link:
Regeneron announces FDA acceptance for sBLA review of Libtayo with chemotherapy for NSCLC
Regeneron announces FDA acceptance for sBLA review of Libtayo with chemotherapy for NSCLC
Pharmaceutical Business Review
Regeneron
FDA
Libtayo
non-small cell lung cancer
Flag link:
Regeneron Could Have a Big Catalyst Coming in 2022
Regeneron Could Have a Big Catalyst Coming in 2022
Motley Fool
Regeneron
Libtayo
cervical cancer
FDA
Sanofi
Flag link:
ESMO21: Libtayo extends survival in first-line NSCLC, challenging Keytruda
ESMO21: Libtayo extends survival in first-line NSCLC, challenging Keytruda
Pharmaforum
Sanofi
Regeneron
Libtayo
ESMO
non-small cell lung cancer
Merck
Keytruda
Flag link:
Regeneron drug extends survival in lung cancer trial, lifting company's hopes in field
Regeneron drug extends survival in lung cancer trial, lifting company's hopes in field
BioPharma Dive
Regeneron
Sanofi
Libtayo
clinical trials
lung cancer
Flag link:
Inovio is going after the 'impossible tumor' left in the dust of new cancer meds
Inovio is going after the 'impossible tumor' left in the dust of new cancer meds
Fierce Biotech
Inovio
glioblastoma
INO-5401
INO-9012
Libtayo
clinical trials
Flag link:
Sanofi, Regeneron’s Libtayo improves survival in cervical cancer patients
Sanofi, Regeneron’s Libtayo improves survival in cervical cancer patients
Pharma Times
Sanofi
Regeneron
Libtayo
cervical cancer
clinical trials
Flag link:
Libtayo scores second OK in two weeks, this time for front-line NSCLC. Can it take on Keytruda?
Libtayo scores second OK in two weeks, this time for front-line NSCLC. Can it take on Keytruda?
Endpoints
Regeneron
Libtayo
non-small cell lung cancer
Merck
Keytruda
Flag link:
Sanofi/Regeneron's Libtayo Wins FDA Approval For A Type Of Skin Cancer
Sanofi/Regeneron's Libtayo Wins FDA Approval For A Type Of Skin Cancer
Yahoo/Benzinga
Sanofi
Regeneron
Libtayo
FDA
advanced basal cell carcinoma
skin cancer
Flag link:
Watch out, Merck: FDA grants Regeneron, Sanofi's Libtayo priority review for coveted first-line use in lung cancer
Watch out, Merck: FDA grants Regeneron, Sanofi's Libtayo priority review for coveted first-line use in lung cancer
Fierce Pharma
Regeneron
Sanofi
Libtayo
FDA
priority review
non-small cell lung cancer
Merck
Keytruda
Flag link:
ESMO: Regeneron and Sanofi gun for Libtayo in first-line NSCLC with fresh survival stats
ESMO: Regeneron and Sanofi gun for Libtayo in first-line NSCLC with fresh survival stats
Fierce Pharma
Libtayo
ESMO
Regeneron
Sanofi
non-small cell lung cancer
Flag link:
Sanofi/Regeneron’s Libtayo set for new skin cancer use
Sanofi/Regeneron’s Libtayo set for new skin cancer use
Pharmaforum
Sanofi
Regeneron
Libtayo
clinical trials
skin cancer
Flag link:
Regeneron pairs with BioNTech on melanoma immunotherapy
Regeneron pairs with BioNTech on melanoma immunotherapy
Pharmaforum
Regeneron
BioNTech
melanoma
Libtayo
vaccines
BNT111
MRNA
Flag link:
Merck treads on Sanofi, Regeneron's turf with Keytruda's latest skin cancer OK
Merck treads on Sanofi, Regeneron's turf with Keytruda's latest skin cancer OK
Fierce Pharma
Merck
Keytruda
FDA
squamous cell carcinoma
Sanofi
Regeneron
Libtayo
Flag link:

Pages